ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Bradley J Monk; Robert L Coleman; Keiichi Fujiwara; Michelle K Wilson; Amit M Oza; Ana Oaknin; David M O’Malley; Domenica Lorusso; Shannon N Westin; Tamar Safra; Thomas J Herzog; Frederik Marmé; Ramez N Eskander; Kevin K Lin; Danny Shih; Sandra Goble; Nikolay Grechko; Stephanie Hume; Lara Maloney; Iain A McNeish; Rebecca S Kristeleit

doi:10.1136/ijgc-2021-002933

Citation Tools

Clinical trial

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Monk BJ, Coleman RL, Fujiwara K, et al

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

International Journal of Gynecologic Cancer 2021;31:1589-1594.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password